Pharmaceutical Technology

SEPTEMBER 21, 2022

Renovacor focuses on offering precision treatments for genetic cardiovascular and mechanistically-related ailments. The most advanced programme of the company is adeno-associated virus (AAV)-based gene therapy, REN-001. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Gene Therapy 147

Gene Therapy Gene Cardiology Genetics 147

STAT News

JULY 12, 2022

The treatment is aimed at a relatively common form of high cholesterol that affects millions of people, a very different population than those normally treated with gene therapies. The company studying the treatment, Verve Therapeutics, announced the news Tuesday. Continue to STAT+ to read the full story…

Gene Editing 98

Gene Editing Gene Therapy Gene Cardiology 98

Scienmag

MAY 17, 2021

Patients’ genetic profile strongly influences size of effect in early-phase trial People with extremely high levels of triglycerides (a type of fat in the blood) and a specific genetic profile saw a substantial reduction in triglycerides after taking the human monoclonal antibody evinacumab compared with those taking a placebo, in a study presented (..)

Genetics 42

Genetics Antibody Trials Gene Therapy 42

Pharma Marketing Network

FEBRUARY 27, 2025

Scientific blogs discussing new advancements in oncology, cardiology, or rare diseases. For example, a LinkedIn article on the future of gene therapy can position a brand as an authority in genetic medicine, attracting biotech investors, researchers, and prescribing physicians.

Branding 52

Branding Marketing Compliance Pharma Companies 52

The Pharma Data

SEPTEMBER 15, 2020

Pfizer’s Rare Disease late-stage pipeline currently includes three gene therapy programs that, if successful, are expected to gain regulatory approval by the end of 2023, with an additional pipeline of 10 preclinical initiatives that are at various stages of maturity. and -50.4%

Gene Therapy 52

Gene Therapy Vaccination Vaccine Trials 52